Maki Nazli, Dey Saibal
Department of Biochemistry and Molecular Biology, Uniformed Services University of the Health Sciences, F. Edward Hébert School of Medicine, 4301 Jones Bridge Road, Bethesda, MD 20814-4799, USA.
Biochem Pharmacol. 2006 Jul 14;72(2):145-55. doi: 10.1016/j.bcp.2006.04.008. Epub 2006 Apr 25.
The drug-transport function of the human P-glycoprotein (Pgp or ABCB1) is inhibited by a number of structurally unrelated compounds, known as modulators or reversing agents. Among them, the thioxanthene derivative flupentixol inhibits Pgp-mediated drug transport by an allosteric mechanism. Unlike most other Pgp modulators, the cis isomer of flupentixol [cis-(Z)-flupentixol] facilitates interaction of Pgp with its transport-substrate [125I]iodoarylazidoprazosin (or [125I]IAAP), yet inhibits transport. In this study, we show that the flupentixol site acts as a common site of interaction for the tricyclic ring-containing modulators thioxanthenes and phenothiazines. The allosteric stimulation of [125I]IAAP binding to Pgp occurs independent of the phosphorylation status of the transporter. Stimulation is retained in purified Pgp reconstituted into proteoliposomes, suggesting no involvement of any other cellular protein in the phenomenon. However, perturbation of the lipid environment of the reconstituted Pgp by nonionic detergent octylglucoside abolishes stimulation by cis-(Z)-flupentixol of [125I]IAAP binding. Extensive trypsin digestion of the [125I]IAAP-labeled Pgp generates a 5.5 kDa fragment with 80% of the stimulated level of labeling associated with it. Sensitivity to inhibition by transport-substrate vinblastine and competitive modulator cyclosporin A suggests that the elevated level of [125I]IAAP binding to the fragment represents a functionally relevant interaction with the substrate site of Pgp. In summary, we demonstrate that allosteric modulation by cis-(Z)-flupentixol is mediated through its interaction with Pgp at a site specific for tricyclic ring-containing Pgp modulators of thioxanthene and phenothiazine backbone, independent of other cellular components and the phosphorylation status of the protein.
人P-糖蛋白(Pgp或ABCB1)的药物转运功能受到许多结构不相关的化合物抑制,这些化合物被称为调节剂或逆转剂。其中,噻吨衍生物氟哌噻吨通过变构机制抑制Pgp介导的药物转运。与大多数其他Pgp调节剂不同,氟哌噻吨的顺式异构体[顺式-(Z)-氟哌噻吨]促进Pgp与其转运底物[125I]碘芳基叠氮哌唑嗪(或[125I]IAAP)的相互作用,但抑制转运。在本研究中,我们表明氟哌噻吨位点是含三环的调节剂噻吨类和吩噻嗪类的共同相互作用位点。[125I]IAAP与Pgp结合的变构刺激发生与转运蛋白的磷酸化状态无关。刺激作用在重组到蛋白脂质体中的纯化Pgp中得以保留,这表明该现象不涉及任何其他细胞蛋白。然而,非离子去污剂辛基葡糖苷对重组Pgp脂质环境的扰动消除了顺式-(Z)-氟哌噻吨对[125I]IAAP结合的刺激作用。对[125I]IAAP标记的Pgp进行广泛的胰蛋白酶消化产生一个5.5 kDa的片段,与之相关的标记刺激水平的80%与之相关。对转运底物长春碱和竞争性调节剂环孢素A抑制的敏感性表明,[125I]IAAP与该片段结合水平的升高代表了与Pgp底物位点的功能相关相互作用。总之,我们证明顺式-(Z)-氟哌噻吨的变构调节是通过其与Pgp在一个特定于噻吨和吩噻嗪骨架的含三环Pgp调节剂的位点相互作用介导的,独立于其他细胞成分和蛋白质的磷酸化状态。